Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Whole spine MRI is not required in investigating uncomplicated paediatric lumbosacral lipoma. A retrospective single-institution review.

Layard Horsfall H, Chari A, Huttunen T, Simcock C, D'Arco F, Thompson D.

Childs Nerv Syst. 2019 Sep 9. doi: 10.1007/s00381-019-04373-z. [Epub ahead of print]

PMID:
31502036
2.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S.

N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.

PMID:
31433920
3.

Subarachnoid haemorrhage with negative initial neurovascular imaging: a systematic review and meta-analysis.

Mohan M, Islim AI, Rasul FT, Rominiyi O, deSouza RM, Poon MTC, Jamjoom AAB, Kolias AG, Woodfield J, Patel K, Chari A, Kirollos R; British Neurosurgical Trainee Research Collaborative.

Acta Neurochir (Wien). 2019 Oct;161(10):2013-2026. doi: 10.1007/s00701-019-04025-w. Epub 2019 Aug 13. Review.

PMID:
31410556
4.

Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.

Chari A, Parikh K, Ni Q, Abouzaid S.

Clin Lymphoma Myeloma Leuk. 2019 Jun 18. pii: S2152-2650(18)31575-1. doi: 10.1016/j.clml.2019.06.007. [Epub ahead of print]

PMID:
31377207
5.

Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).

Chari A, Romanus D, DasMahapatra P, Hoole M, Lowe M, Curran C, Campbell S, Bell JA.

Oncologist. 2019 Aug 1. pii: theoncologist.2018-0724. doi: 10.1634/theoncologist.2018-0724. [Epub ahead of print]

PMID:
31371520
6.

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.

Usmani SZ, Nahi H, Mateos MV, van de Donk NWCJ, Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Hellemans P, Masterson T, Clemens PL, Luo M, Liu K, San-Miguel J.

Blood. 2019 Aug 22;134(8):668-677. doi: 10.1182/blood.2019000667. Epub 2019 Jul 3.

PMID:
31270103
7.

Structural and Functional Analyses of the Human PDH Complex Suggest a "Division-of-Labor" Mechanism by Local E1 and E3 Clusters.

Prajapati S, Haselbach D, Wittig S, Patel MS, Chari A, Schmidt C, Stark H, Tittmann K.

Structure. 2019 Jul 2;27(7):1124-1136.e4. doi: 10.1016/j.str.2019.04.009. Epub 2019 May 23.

PMID:
31130485
8.

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA.

Br J Haematol. 2019 Aug;186(4):549-560. doi: 10.1111/bjh.15969. Epub 2019 May 24.

PMID:
31124580
9.

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P.

Blood. 2019 Aug 1;134(5):421-431. doi: 10.1182/blood.2019000722. Epub 2019 May 21.

PMID:
31113777
10.

Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series.

Sklar BA, Gervasio KA, Leng S, Ghosh A, Chari A, Wu AY.

BMC Ophthalmol. 2019 May 14;19(1):110. doi: 10.1186/s12886-019-1118-x.

11.

Dex-CSDH randomised, placebo-controlled trial of dexamethasone for chronic subdural haematoma: report of the internal pilot phase.

Edlmann E, Thelin EP, Caldwell K, Turner C, Whitfield P, Bulters D, Holton P, Suttner N, Owusu-Agyemang K, Al-Tamimi YZ, Gatt D, Thomson S, Anderson IA, Richards O, Gherle M, Toman E, Nandi D, Kane P, Pantaleo B, Davis-Wilkie C, Tarantino S, Barton G, Marcus HJ, Chari A, Belli A, Bond S, Gafoor R, Dawson S, Whitehead L, Brennan P, Wilkinson I, Kolias AG, Hutchinson PJA; Dex-CSDH trial collaborative and BNTRC collaborative.

Sci Rep. 2019 Apr 10;9(1):5885. doi: 10.1038/s41598-019-42087-z.

12.

Correction to: Dexamethasone for adult patients with a symptomatic chronic subdural haematoma (Dex-CSDH) trial: study protocol for a randomised controlled trial.

Kolias AG, Edlmann E, Thelin EP, Bulters D, Holton P, Suttner N, Owusu-Agyemang K, Al-Tamimi YZ, Gatt D, Thomson S, Anderson IA, Richards O, Whitfield P, Gherle M, Caldwell K, Davis-Wilkie C, Tarantino S, Barton G, Marcus HJ, Chari A, Brennan P, Belli A, Bond S, Turner C, Whitehead L, Wilkinson I, Hutchinson PJ; British Neurosurgical Trainee Research Collaborative (BNTRC) and Dex-CSDH Trial Collaborators.

Trials. 2019 Mar 18;20(1):175. doi: 10.1186/s13063-019-3283-x.

13.

Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach.

Laganà A, Beno I, Melnekoff D, Leshchenko V, Madduri D, Ramdas D, Sanchez L, Niglio S, Perumal D, Kidd BA, Miotto R, Shaknovich R, Chari A, Cho HJ, Barlogie B, Jagannath S, Dudley JT, Parekh S.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00019. Epub 2018 Aug 8.

14.

Disproportionately Large Communicating Fourth Ventricle: Pearls for Diagnosis and Management.

Chari A, Karponis D, Craven CL, Khan AA, Thorne L.

Cureus. 2018 Nov 5;10(11):e3547. doi: 10.7759/cureus.3547.

15.

Daratumumab-induced transient myopic shift.

Mavrommatis MA, Jung H, Chari A, Barlogie B, Chelnis JG.

Am J Ophthalmol Case Rep. 2018 Dec 18;13:116-118. doi: 10.1016/j.ajoc.2018.12.017. eCollection 2019 Mar.

16.

Dexamethasone for adult patients with a symptomatic chronic subdural haematoma (Dex-CSDH) trial: study protocol for a randomised controlled trial.

Kolias AG, Edlmann E, Thelin EP, Bulters D, Holton P, Suttner N, Owusu-Agyemang K, Al-Tamimi YZ, Gatt D, Thomson S, Anderson IA, Richards O, Whitfield P, Gherle M, Caldwell K, Davis-Wilkie C, Tarantino S, Barton G, Marcus HJ, Chari A, Brennan P, Belli A, Bond S, Turner C, Whitehead L, Wilkinson I, Hutchinson PJ; British Neurosurgical Trainee Research Collaborative (BNTRC) and Dex-CSDH Trial Collaborators.

Trials. 2018 Dec 4;19(1):670. doi: 10.1186/s13063-018-3050-4. Erratum in: Trials. 2019 Mar 18;20(1):175. Zolnouria, Ardalan [corrected to Zolnourian, Ardalan].

17.

Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies.

Lancman G, Arinsburg S, Jhang J, Cho HJ, Jagannath S, Madduri D, Parekh S, Richter J, Chari A.

Front Immunol. 2018 Nov 15;9:2616. doi: 10.3389/fimmu.2018.02616. eCollection 2018. Review.

18.

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.

Chari A, Lonial S, Mark TM, Krishnan AY, Stockerl-Goldstein KE, Usmani SZ, Londhe A, Etheredge D, Fleming S, Liu B, Ukropec J, Lin TS, Jagannath S, Nooka AK.

Cancer. 2018 Nov 15;124(22):4342-4349. doi: 10.1002/cncr.31706. Epub 2018 Nov 5.

19.

Pharmacological management of post-traumatic seizures in adults: current practice patterns in the UK and the Republic of Ireland.

Mee H, Kolias AG, Chari A, Ercole A, Lecky F, Turner C, Tudur-Smith C, Coles J, Anwar F, Belli A, Manford M, Ham T, McMahon C, Bulters D, Uff C, Duncan JS, Wilson MH, Marson AG, Hutchinson PJ.

Acta Neurochir (Wien). 2019 Mar;161(3):457-464. doi: 10.1007/s00701-018-3683-9. Epub 2018 Oct 1.

20.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

21.

Pulsatile versus non-pulsatile tinnitus in idiopathic intracranial hypertension.

Funnell JP, Craven CL, Thompson SD, D'Antona L, Chari A, Thorne L, Watkins LD, Toma AK.

Acta Neurochir (Wien). 2018 Oct;160(10):2025-2029. doi: 10.1007/s00701-018-3587-8. Epub 2018 Jul 16.

PMID:
30014363
22.

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.

Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, Hajek R, Groarke J, Lyon AR, Batty GN, Ro S, Huang M, Iskander KS, Lenihan D.

Blood Adv. 2018 Jul 10;2(13):1633-1644. doi: 10.1182/bloodadvances.2017015545. Review.

23.

Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.

Wu V, Moshier E, Leng S, Barlogie B, Cho HJ, Jagannath S, Madduri D, Mazumdar M, Parekh S, Chari A.

Blood Adv. 2018 Jun 26;2(12):1470-1479. doi: 10.1182/bloodadvances.2018016998. Erratum in: Blood Adv. 2018 Sep 11;2(17):2186.

24.

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.

Richardson PG, Hofmeister CC, Rosenbaum CA, Htut M, Vesole DH, Berdeja JG, Liedtke M, Chari A, Smith SD, Lebovic D, Raje N, Byrne C, Liao E, Gupta N, Bacco AD, Estevam J, Berg D, Baz R.

Br J Haematol. 2018 Jul;182(2):231-244. doi: 10.1111/bjh.15394. Epub 2018 Jun 25.

25.

Imipridone ONC201: combination therapy in hematologic malignancies.

Chari A, Barlogie B.

Cell Cycle. 2018;17(16):1947-1948. doi: 10.1080/15384101.2018.1490861. Epub 2018 Sep 11. No abstract available.

26.

Cryo-EM in drug discovery: achievements, limitations and prospects.

Renaud JP, Chari A, Ciferri C, Liu WT, Rémigy HW, Stark H, Wiesmann C.

Nat Rev Drug Discov. 2018 Jul;17(7):471-492. doi: 10.1038/nrd.2018.77. Epub 2018 Jun 8. Review.

PMID:
29880918
27.

Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat.

Chari A, Bhor M, Eldjerou L, Gilligan AM, Urniasz A, Globe D, Stetsovsky D, Varker H, Davis B, Bonafede M, Talcott J.

Future Oncol. 2018 Sep;14(21):2149-2160. doi: 10.2217/fon-2017-0727. Epub 2018 May 30.

PMID:
29846095
28.

Corrigenda: Residual enhancing disease after surgery for glioblastoma: evaluation of practice in the United Kingdom.

Ma R, Chari A, Brennan PM, Alalade A, Anderson I, Solth A, Marcus HJ, Watts C; British Neurosurgical Trainee Research Collaborative.

Neurooncol Pract. 2018 May;5(2):72. doi: 10.1093/nop/npy017. Epub 2018 May 10.

29.

Residual enhancing disease after surgery for glioblastoma: evaluation of practice in the United Kingdom.

Ma R, Chari A, Brennan PM, Alalade A, Anderson I, Solth A, Marcus HJ, Watts C; British Neurosurgical Trainee Research Collaborative .

Neurooncol Pract. 2018 May;5(2):74-81. doi: 10.1093/nop/npx023. Epub 2017 Sep 27. Erratum in: Neurooncol Pract. 2018 May;5(2):72.

30.

Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.

Chari A, Larson S, Holkova B, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Valent J, Lunning M, Usmani SZ, Anderson LD Jr, Chang L, Lee Y, Pak Y, Salman Z, Graef T, Bilotti E, Chhabra S.

Leuk Lymphoma. 2018 Nov;59(11):2588-2594. doi: 10.1080/10428194.2018.1443337. Epub 2018 Apr 4.

PMID:
29616843
31.

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.

Gandhi UH, Senapedis W, Baloglu E, Unger TJ, Chari A, Vogl D, Cornell RF.

Clin Lymphoma Myeloma Leuk. 2018 May;18(5):335-345. doi: 10.1016/j.clml.2018.03.003. Epub 2018 Mar 14. Review.

32.

Intracranial pressure in patients with papilloedema.

Funnell JP, Craven CL, D'Antona L, Thompson SD, Chari A, Thorne L, Watkins LD, Toma AK.

Acta Neurol Scand. 2018 Aug;138(2):137-142. doi: 10.1111/ane.12922. Epub 2018 Mar 12.

PMID:
29532475
33.

The evolution of British neurosurgical selection and training over the past decade.

Alamri A, Chari A, McKenna G, Kamaly-Asl I, Whitfield PC.

Med Teach. 2018 Jun;40(6):610-614. doi: 10.1080/0142159X.2018.1444744. Epub 2018 Mar 8.

PMID:
29519179
34.

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States.

Hari P, Romanus D, Palumbo A, Luptakova K, Rifkin RM, Tran LM, Raju A, Farrelly E, Noga SJ, Blazer M, Chari A.

Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):152-160. doi: 10.1016/j.clml.2017.12.012. Epub 2018 Jan 5.

35.

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK.

J Clin Oncol. 2018 Mar 20;36(9):859-866. doi: 10.1200/JCO.2017.75.5207. Epub 2018 Jan 30.

PMID:
29381435
36.

A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.

Chari A, Cho HJ, Dhadwal A, Morgan G, La L, Zarychta K, Catamero D, Florendo E, Stevens N, Verina D, Chan E, Leshchenko V, Laganà A, Perumal D, Mei AH, Tung K, Fukui J, Jagannath S, Parekh S.

Blood Adv. 2017 Aug 21;1(19):1575-1583. doi: 10.1182/bloodadvances.2017007427. eCollection 2017 Aug 22.

37.

The effect of novel therapies in high-molecular-risk multiple myeloma.

Lancman G, Tremblay D, Barley K, Barlogie B, Cho HJ, Jagannath S, Madduri D, Moshier E, Parekh S, Chari A.

Clin Adv Hematol Oncol. 2017 Nov;15(11):870-879. Review.

38.

Health care at birth and infant mortality: Evidence from nighttime deliveries in Nigeria.

Okeke EN, Chari AV.

Soc Sci Med. 2018 Jan;196:86-95. doi: 10.1016/j.socscimed.2017.11.017. Epub 2017 Nov 12.

PMID:
29161641
39.

The British Neurosurgical Trainee Research Collaborative: Five years on.

Chari A, Jamjoom AA, Edlmann E, Ahmed AI, Coulter IC, Ma R, May P, Brennan PM, Hutchinson PJA, Kolias AG; British Neurosurgical Trainee Research Collaborative.

Acta Neurochir (Wien). 2018 Jan;160(1):23-28. doi: 10.1007/s00701-017-3351-5. Epub 2017 Nov 4. Review.

40.

Prospective, multicentre study of external ventricular drainage-related infections in the UK and Ireland.

Jamjoom AAB, Joannides AJ, Poon MT, Chari A, Zaben M, Abdulla MAH, Roach J, Glancz LJ, Solth A, Duddy J, Brennan PM, Bayston R, Bulters DO, Mallucci CL, Jenkinson MD, Gray WP, Kandasamy J, Hutchinson PJ, Kolias AG, Ahmed AI; British Neurosurgical Trainee Research Collaborative.

J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):120-126. doi: 10.1136/jnnp-2017-316415. Epub 2017 Oct 25.

41.

Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma.

Chari A, Arinsburg S, Jagannath S, Satta T, Treadwell I, Catamero D, Morgan G, Feng H, Uhlar C, Khan I, Doshi P, Usmani S.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):44-51. doi: 10.1016/j.clml.2017.09.002. Epub 2017 Sep 19.

42.

Intraparenchymal intracranial pressure monitoring for hydrocephalus and cerebrospinal fluid disorders.

Chari A, Dasgupta D, Smedley A, Craven C, Dyson E, Matloob S, Thompson S, Thorne L, Toma AK, Watkins L.

Acta Neurochir (Wien). 2017 Oct;159(10):1967-1978. doi: 10.1007/s00701-017-3281-2. Epub 2017 Aug 10.

43.

Characteristics of Vitamin B12 Deficiency in Patients With Plasma Cell Disorders.

Braschi C, Doucette J, Chari A.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e65-e69. doi: 10.1016/j.clml.2017.07.001. Epub 2017 Jul 12.

PMID:
28757000
44.

Management of Patients With Hepatitis C Virus, Monoclonal Gammopathy of Undetermined Significance, and Multiple Myeloma.

Hannaford A, Del Bello D, Leng S, Chari A, Perumalswami P, Dieterich D, Branch A.

J Investig Med High Impact Case Rep. 2017 Apr 26;5(2):2324709617696854. doi: 10.1177/2324709617696854. eCollection 2017 Apr-Jun.

45.

Outcomes of salvage autologous stem cell transplantation for multiple myeloma with cytopenias and exposure to novel agents.

Tremblay D, Lancman G, Moshier E, Bar N, Jagannath S, Chari A.

Bone Marrow Transplant. 2017 Oct;52(10):1468-1470. doi: 10.1038/bmt.2017.160. Epub 2017 Jul 24. No abstract available.

PMID:
28737774
46.

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.

van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R.

Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):555-562. doi: 10.1016/j.clml.2017.06.020. Epub 2017 Jul 4.

PMID:
28735890
47.

Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.

Laganà A, Perumal D, Melnekoff D, Readhead B, Kidd BA, Leshchenko V, Kuo PY, Keats J, DeRome M, Yesil J, Auclair D, Lonial S, Chari A, Cho HJ, Barlogie B, Jagannath S, Dudley JT, Parekh S.

Leukemia. 2018 Jan;32(1):120-130. doi: 10.1038/leu.2017.197. Epub 2017 Jun 23.

PMID:
28642592
48.

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S.

Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21.

49.

A Retrospective Cohort Study to Assess Patient and Physician Reported Outcome Measures After Decompressive Hemicraniectomy for Malignant Middle Cerebral Artery Stroke.

Budhdeo S, Kolias AG, Clark DJ, Chari A, Hutchinson PJ, Warburton EA.

Cureus. 2017 May 10;9(5):e1237. doi: 10.7759/cureus.1237.

50.

Long-range allosteric regulation of the human 26S proteasome by 20S proteasome-targeting cancer drugs.

Haselbach D, Schrader J, Lambrecht F, Henneberg F, Chari A, Stark H.

Nat Commun. 2017 May 25;8:15578. doi: 10.1038/ncomms15578.

Supplemental Content

Support Center